Good Old Genentech

Just when you thought it was over for the biotech sector, Genentech delivers some good news. Their Avastin drug is effective against lung cancer. Analyst are already estimating potential sales of $500-$700 million for the company in the lung cancer market. I own a few shares of Genentech in my Roth IRA, I just wish I had more! Well this is exactly what the biotech sector needed, some good news. I'll take this any day...